Genome-wide association study reveals the unique genetic structure of active blood donors

Jonna Clancy*[1], Jarkko Toivonen[1], Jouni Lauronen[1], Satu Koskela[1], Jukka Partanen[1], FinnGen[2], Mikko Arvas[1], Jarmo Ritari[1]

[1] Finnish Red Cross Blood Service, Vantaa, Finland

[2] List of FinnGen members is available as a supplementary file

* jonna.clancy@veripalvelu.fi

Abstract

The healthy donor effect (HDE) refers to the observed lower mortality rate among blood donors compared to the general population. While membership biases such as HDE arise due to healthier individuals being more likely to participate, the extent to which it is influenced by genetic differences remains largely unclear. To elucidate the genetic basis of HDE, we conducted a genome-wide association study (GWAS) involving 53,688 active blood donors with extensive donation histories and 228,060 controls from biobank cohorts within the FinnGen project. Our results identified 2,973 genome-wide significant loci associated with repeated blood donation and impacting several health-related endpoints and protein level alteration. Importantly, significant variants related not only to blood groups but also influenced the predisposition to somatic and mental diseases, suggesting that HDE is not solely tied to blood donation eligibility criteria. In conclusion, in this work we show that HDE is partially explained by genetic factors affecting various disease categories.

Keywords: blood donor, biobank, healthy donor effect, GWAS, blood group, HLA

Introduction

Blood donors play an important role as an excellent healthy control cohort in genetics and biomedical research due to their commitment and altruistic nature[1]. Their voluntary and frequent blood donations offer unique opportunities for longitudinal sampling. In addition, blood donors exhibit positive attitudes toward the use of their samples and data in scientific research, if not directly required in patient care[2,3].

However, blood donors are a highly selected population due to the health status criteria they must meet to be eligible to donate blood. Along with a general survey of the donor's current state of health, basic restrictions on blood donation suitability include serious illnesses such as severe cardiovascular conditions, cancer and epilepsy[4]. Some conditions that restrict blood donation suitability have strong well-known genetic background, such as the association of *HLA* genes in type 1 diabetes (T1D)[5] or in certain autoimmune diseases[6–8]. As a minimum hemoglobin level is required for donation eligibility, genetic variants affecting iron and hemoglobin levels may also cause donor selection. Due to these factors, blood donor selection results in a known phenomenon, *healthy donor effect*, HDE, which can lead to detrimental effects in a research setting if not taken into account[9].

Comprehensive selection of different blood groups, and especially a sufficient amount of emergency blood type O RhD neg suitable for most recipients, are basic requirements in blood banks. Due to the high need for emergency blood O RhD neg and strong immunogenicity of certain blood group antigens, such as ABO, Rh and Kell[10–13], donor recruitment is partially based on blood group genotype and results in enrichment of certain blood group antigens in a blood donor pool. Well known associations between ABO blood group antigens and cardiovascular conditions exist, more precisely between red cell antigen O and reduced thromboembolic diseases[14,15]. Risk for bleeding disorder, Von Willebrand disease, is known to be higher among individuals with red cell O antigen[16]. Pregnancy-induced hypertension has been previously described to occur more in RhD positive

53 individuals[15]. Moreover, in certain medical conditions, such as in hemochromatosis, blood donation
54 may be beneficial, and donors with these conditions may be enriched in the blood donor
55 population[17].

56 Enrichment of genetic variants with known disease associations or biological functions may result in
57 unpredicted effects in biomedical research. To reveal the genetic qualities of blood donors and to
58 understand the possible genetic selection leading to the HDE, we conducted a genome-wide
59 association study (GWAS) between the Finnish Red Cross Blood Service Biobank, and FinnGen (Figure
60 1). In addition, our aim was to discover genetic variants potentially contributing to personalized
61 blood donation and transfusion.

62 To our knowledge, no previous genome studies have focused on the possible selection bias caused
63 by blood group and health questionnaire-based requirement of blood donors. We found altogether
64 2,973 genome-wide significant associations. Genetic correlation analysis revealed strong negative
65 correlation between blood donorship and diseases such as mental disorders, pain disorders,
66 cardiovascular diseases, addiction disorders, autoimmune disorders, and Alzheimer's disease. *HLA*
67 association analysis confirmed the enrichment of hemochromatosis related *HLA* alleles and the
68 lower occurrence of autoimmune related *HLA* alleles in the blood donor population and indicated a
69 risk SNP tagging both hemochromatosis and autoimmune related *HLA* alleles. The genome-wide
70 significant variants associated with 112 plasma protein level alterations. The results of this study
71 demonstrate the genetic basis of the HDE, which is not limited to immediate blood donorship
72 inclusion criteria.



Figure 1 General workflow of the study. GWAS was performed on 53,688 cases (blood donors) and 228,060 controls. Genome wide significant GWAS results were fine-mapped and further used for several association analyses. Genetic correlation of 2470 phenotypes to blood donorship were calculated based on GWAS results. In addition, we imputed red cell antigens and tested their association to blood donorship. Previously imputed HLA alleles in FinnGen project were used to perform association analysis to blood donorship. Results of the previously performed protein quantitative trait loci analysis were used to analyze the association of the fine-mapped variants to protein level alteration. *Figure is created with BioRender.com.*

Results

Demographic information and differences in diagnoses between the two cohorts are described in Table 1. In both sexes the blood donors were younger, taller and in males also heavier. More female participants were seen in the blood donor cohort. A clear and significant difference between the two cohorts was seen in both sexes in all the diagnose groups apart from ´XVI Certain conditions

89 originating in the perinatal period′ where more incidents were found among blood donors in both

90 sexes. FinnGen cohort consisted of donors in hospital biobanks but also donors in population cohorts

91 and in occupational health (Supplementary Table 1).

92

	Females		Males	
	Blood donors	FinnGen	Blood donors	FinnGen
Median age at sampling, years (IQR)	44.47 (18.2-70.8)	62.7 (36.2-89.2)	50.26 (25.5-75.0)	70.46 (51.3-89.6)
Sex, n (%)	32,460 (60.46)	120,279 (52.74)	21,228 (39.54)	107,781 (47.26)
Median weight, kg (IQR)	72 (54-90) [a]	72 (51-93) [a]	86 (68-104)	84 (64-104)
Median height, cm (IQR)	167 (159-175)	164 (156-172)	180 (171-189)	177 (168-186)
Median BMI (IQR)	25.83 (19.3-32.4)	26.64 (19.1-34.2)	26.58 (21.6-31.6)	26.88 (21.2-32.6)
FinnGen endpoint category [b]				
I Certain infectious and parasitic diseases (AB1)	7,466 (23)	47,901 (39.82)	5,565 (26.22)	48,487 (44.99)
II Neoplasms from cancer register (ICD-O-3)	968 (2.98)	34,299 (28.52)	791 (3.73)	38,891 (36.08)
II Neoplasms from hospital discharges (CD2)	6,960 (21.44)	67,026 (55.73)	2,804 (13.21)	52,708 (48.9)
III Blood and immune system (D3)	964 (2.97)	17,017 (14.15)	534 (2.52)	15,606 (14.48)
IV Endocrine, nutritional and metabolic (E4)	10,269 (31.64)	83,780 (69.65)	3,029 (14.27)	58,530 (54.3)
IX Circulatory system (I9)	6,276 (19.33)	69,429 (57.72)	4,587 (21.61)	78,876 (73.18)
V Mental and behavioural disorders (F5)	7,871 (24.25)	42,676 (35.48)	3,648 (17.18)	33,080 (30.69)
VI Nervous system (G6)	6,431 (19.81)	54,710 (45.49)	4,501 (21.2)	51,142 (47.45)
VII Eye and adnexa (H7)	8,088 (24.92)	58,567 (48.69)	4,660 (21.95)	47,174 (43.77)
VIII Ear and mastoid process (H8)	5,316 (16.38)	29,249 (24.32)	3,893 (18.34)	26,561 (24.64)
X Respiratory system (J10)	14,408 (44.39)	69,022 (57.38)	11,532 (54.32)	69,209 (64.21)
XI Digestive system (K11)	27,542 (84.85)	106,938 (88.91)	17,037 (80.26)	90,482 (83.95)
XII Skin and subcutaneous tissue (L12)	7,710 (23.75)	43,402 (36.08)	4,096 (19.3)	32,486 (30.14)
XIII Musculoskeletal and connective tissue (M13)	13,715 (42.25)	83,931 (69.78)	9,118 (42.95)	68,570 (63.62)
XIV Genitourinary system (N14)	17,334 (53.4)	91,665 (76.21)	4,463 (21.02)	49,729 (46.14)
XIX Injury, poisoning, external (ST19)	15,936 (49.09)	73,725 (61.29)	13,051 (61.48)	70,375 (65.29)
XV Pregnancy, childbirth and the puerperium (O15)	20,560 (63.34)	86,799 (72.16)	0 (0)	0 (0)
XVI Perinatal period (P16)	535 (1.65)	1,000 (0.83)	263 (1.24)	514 (0.48)
XVII Congenital malformations (Q17)	2,018 (6.22)	10,032 (8.34)	1,231 (5.8)	7,258 (6.73)
XVIII Abnormal clinical and laboratory findings (R18)	16,800 (51.76)	93,458 (77.7)	9,125 (42.99)	80,419 (74.61)
XX External causes of mortality (VWXY20)	13,025 (40.13)	64,874 (53.94)	10,741 (50.6)	62,034 (57.56)
XXI Contact with health services (Z21)	24,581 (75.73)	10,4068 (86.52)	10,544 (49.67)	72,915 (67.65)
XXII Codes for special purposes (U22)	1,417 (4.37)	5,906 (4.91)	595 (2.8)	4,310 (4)

[a] Not significant
[b] Shortened for clarity

93

94 Table 1 Demographic information of the cohorts. Age, sex, height, weight, BMI and FinnGen
95 endpoint categories in blood donors and FinnGen cohort are shown. Apart from weight in females,
96 difference between the cohorts in each phenotype was statistically significant.
97

98

99 Genome-wide association analysis

100 Genome-wide association analysis revealed 2,973 significant ($p < 5x10^{-8}$) genetic loci associated with

101 blood donorship. After fine-mapping, 5 coding (4 missense and 1 inframe deletion) and 36 non-

102 coding variants were detected (Figure 2A). In addition to these 41 variants, 5 non-coding lead
103 variants in the extended MHC region (Figure 2B and C) were included in the downstream analyses
104 (Table 2).

105 The strongest genome-wide associations were seen in variants related to blood group antigens:
106 rs55794721, $p = 8.88x10^{-89}$, in chromosome 1, rs687621, $p = 5.70x10^{-81}$, in chromosome 9 in *ABO*
107 gene and rs8176058, $p = 1.16x10^{-31}$, in chromosome 7 in *KEL* gene (Figure 1A, Table 2).

108 Despite of the adjustment of the GWAS for BMI, we observed significant GWAS variants known to
109 influence height, weight, and BMI. rs66781921, an inframe deletion variant in chr2, previously
110 shown to have a negative association to height, weight and body mass index[18], was rarer in blood
111 donors (beta = -1.97, $p = 1.89 \times 10^{-11}$). Missense variant rs34811474, previously shown to be
112 negatively associated with body mass index[18], was seen to be more frequent in blood donors (beta =
113 0.064, $p = 1.21 \times 10^{-12}$). Variants rs10947114 ($p = 2.88 \times 10^{-09}$, beta = -0.055), rs3130906 ($p = 5.17 \times$
114 10^{-11}, beta = -0.055) and rs4713637 ($p = 1.39 \times 10^{-08}$, beta = -0.047), previously described to be
115 associated with spondylopathies and celiac disease[18], were negatively associated with blood
116 donorship. A rare intron variant, rs528492111, in chromosome 3 previously shown to have a weak
117 association to benign neoplasm of conjunctiva[18], was more frequent in blood donors (beta = 1.87, p
118 $= 4.09 \times 10^{-10}$).

119 All the fine-mapped and MHC lead variants in the are listed in Table 2.



Figure 2 A) Manhattan plot of the genome-wide association study of blood donorship. B) Extended MHC region of the chromosome 6 of the GWAS. C) Chromosome 6 association study adjusted for type 1 diabetes, T1D. Red dot indicates fine-mapped variants in panel A and in panels B and C the highest variant in each peak reaching the genome wide significance, $<5 \times 10^{-8}$. The name of the nearest gene is shown for these variants if the p-value is $\leq 5 \times 10^{-9}$. The horizontal line has been set to 5×10^{-8}.

	Genome wide association study					pQTL
rs ID	p-value	Beta	Effect	Target gene	Nearest	Target protein
rs66781921	1,89E-11	-1,973	inframe deletion	NCL	SNORD82	-
rs1135071	2,93E-13	-0,573	missense	HBB	HBB	AHSP
rs199598395	1,55E-25	-0,383	missense	RNF43	SUPT4H1	FTL, HAMP, FGF23
rs8176058	1,16E-31	-0,327	missense	KEL	KEL	KEL
rs191302298	3,89E-08	-0,292	intron	LINC01411	MSX2	-
rs10096658	1,35E-08	-0,277	intron	ZFPM2	LRP12	-
rs62113181	8,06E-09	-0,135	intron	KDM4B	KDM4B	-
rs75738358	4,89E-08	-0,080	intergenic	NA	MIR4801	-
rs12539059	5,68E-09	-0,071	downstream gene	COL26A1	LINC01007	KLK11
rs9272324	1,36E-16	-0,064	intron		HLA-DQA1	HERC5, METTL2B, MICB, HLA-DRA, C4B*
rs36035346	5,48E-09	-0,062	intron	CRTC1	CRTC1	-
rs60678519	1,06E-08	-0,055	downstream gene	AC079780,1	RPS2P32	GPNMB
rs10947114	2,88E-09	-0,055	intron		SFTA2	DDR1
rs3130906	5,17E-11	-0,055	intron		HCP5	MICA, CDSN, MICB
rs80319585	1,92E-08	-0,055	intron	KCNMA1	KCNMA1	-
rs7795945	1,28E-09	-0,049	intron	PCLO	PCLO	-
rs34483988	1,65E-08	-0,049	intron	FAM171B	FAM171B	-
rs6775319	2,17E-09	-0,048	intron	SATB1-AS1	SATB1	-
rs7907026	4,63E-10	-0,048	intergenic	NA	SORCS3	-
rs3806234	5,16E-09	-0,047	upstream gene	SNAPIN	SNAPIN	-
rs4713637	1,39E-08	-0,047	intergenic		LINC00336	-
rs62083414	5,35E-09	-0,046	intron	DCC	DCC	-
rs207350	3,03E-08	-0,045	intergenic	NA	LCORL	-
rs594398	1,18E-08	-0,044	intron	SUMO2P17	ATP5G1	-
rs10880819	2,64E-08	0,043	downstream gene	RF00019	ALG10B	-
rs35440643	4,54E-08	0,044	intron	ZNF638	ZNF638	-
rs10166897	1,57E-08	0,044	intron	MAPRE3	MAPRE3	CGREF1
rs113236240	6,53E-09	0,045	intron	PPCDC	PPCDC	MPI, PPCDC
rs55763604	2,84E-08	0,049	intron	BNC2	BNC2	-
rs55732343	2,31E-10	0,049	regulatory region	NA	SLC9A1	-
rs9968910	1,12E-09	0,050	intergenic	NA	HIST1H1C	-
rs5821444	7,98E-09	0,051	3 prime UTR	C17orf58	C17orf58	-
rs6498415	5,47E-10	0,053	intron	U91319,1	SHISA9	-
rs12444334	1,51E-09	0,053	intron	GAS8	C16orf3	CDH15
rs11675100	3,88E-09	0,054	intron	AC007100,1	MIR4432	-
rs9367942	3,81E-08	0,055	intron	STMND1	STMND1	-
rs61937595	1,25E-08	0,062	intron	R3HDM2	R3HDM2	INHBC
rs34811474	1,21E-12	0,064	missense	ANAPC4	ANAPC4	-
rs1500956	5,14E-10	0,075	intron	PDE4B	PDE4B	-
rs77448558	1,28E-08	0,078	intergenic	NA	GRIK2	-
rs10268629	1,71E-09	0,078	intergenic	NA	TAC1	-
rs75350584	1,58E-08	0,094	intron	DLEU1	ST13P4	-
rs687621	5,70E-81	0,147	intron	ABO	ABO	63 different
rs55794721	8,88E-89	0,157	upstream gene	SYF2	SYF2	ICAM4
rs118101548	1,90E-08	0,299	intron	POLD1	POLD1	-
rs528492111	4,09E-10	1,875	intron	WDR6	WDR6	-

Table 2. Fine-mapped and MHC lead variants. Significance, effect size, the most serious effect and nearest gene for each variant is shown. If the variant was associated with altering protein expression levels, the target proteins are shown.

141 Genetic correlation

142 Altogether 593 phenotypes were negatively correlated with blood donorship (FDR < 0.05,
143 Supplementary file 2). Height was the only phenotype showing weak positive correlation with blood
144 donorship, r_g = 0.07 (Figure 3A) despite the GWAS having been adjusted for BMI. Phenotypes
145 associated with some of the individual variants detected by the GWAS with a relatively strong effect
146 size did not show strong correlation with blood donorship. In turn, some phenotypes associated with
147 individual variants with small effect size in GWAS were relatively strongly correlated to blood
148 donorship (Figure 3B).

149 Blood donorship was negatively correlated with r_g < -0.5 to 30 phenotypes (Supplementary file 2).
150 The strongest negative correlation (r_g < -0.6) in blood donors was seen with Anemias (r_g = -0.66, FDR
151 = 2.81 x 10^{-112}), ´Other reaction to severe stress and adjustment disorders´ (r_g = -0.64, FDR = 3.36 x
152 10^{-40}) and ´Other disorders of teeth and supporting structures´ (r_g = -0.62, FDR = 2.74x10^{-03}).
153 Furthermore, negative correlation was observed in phenotypes such as autoimmune diseases (r_g = -
154 0.33, FDR = 1.87 x 10^{-52}), cardiovascular diseases (excluding rheumatic etc) (r_g = -0.42, FDR = 3.79 x
155 10^{-64}) and bleeding disorders (r_g = -0.39, largest FDR = 7.10 x 10^{-11}) (Figure 3C). In addition, negative
156 correlation to blood donorship was observed in phenotypes such as addiction disorders (r_g = -0.33,
157 largest FDR = 7.09 x 10^{-04}), pain disorders (r_g = -0.45, largest FDR = 1.41 x 10^{-10}) and Alzheimer's
158 disease (r_g = -0.24, FDR = 0.03) which are not directly restricted by blood donation eligibility criteria,
159 but which undeniably effect on donation suitability or donor's knowledge on their current state of
160 health. Another example of phenotypes not directly restricted by blood donation eligibility but with
161 relatively strong negative correlation towards blood donorship are infectious phenotypes, such as
162 acute bronchitis (r_g = -0.58, FDR = 1.76 x 10^{-16}) and 'other or unspecified bacterial infection' (r_g = -
163 0.50, FDR = 1.83 x 10^{-09}) (Figure 3A, Supplementary file 2). Furthermore, protective negative
164 correlation with viral hepatitis was observed among blood donors (r_g = -0.51, FDR = 1.88 x 10^{-07}).

Although blood-borne viral diseases are an obstacle to blood donation, it is not assumed that the blood donor population has a protective inheritance against these viral diseases.



Figure 3. Genetic correlation of blood donorship to 594 phenotypes. A) Genetic correlation of 40 phenotypes representing the strongest negative and strongest positive correlation to blood donorship. B) For each of the 46 variants and their most significantly associated FinnGen phenotypes the effect size of the variant and the genetic correlation of the phenotype to blood donorship is shown. The phenotype is labeled when the absolute value of the effect size is higher than 0.25. The vertical bars indicate the standard error of the genetic correlation estimate. C) Genetic correlation matrix of selected phenotypes. Pain disorders, mental disorders, bleeding disorders and addiction disorders have been grouped from several phenotypes belonging to same phenotype category and average genetic correlation is shown. This results in some of the diagonal elements being less than one.

178 Blood group antigen related associations

179 To understand whether blood donor selection leads to enrichment of blood groups in the blood
180 donors, we evaluated the association of imputed red cell antigens with blood donorship using a
181 logistic regression model. The model revealed a strong negative association for blood group antigens
182 Kell, RhD, and AB and a positive association for blood group antigen O (Figure 4A). Results of the
183 GWAS covariates and red cell antigens are available in Supplementary file 2.

184 We further analyzed the blood group related significant GWAS variants in chromosomes 1, 7 and 9
185 with linear regression models. Lead variant in chromosome 1, rs55794721, was associated with the
186 Rh blood group system (previously shown to be associated with height[18]). Rh antigens E, C and D
187 were negatively associated with rs55794721, whereas e and c antigens of the most common Rh
188 negative haplotype in the Caucasoid population, dce[11], were positively associated with rs55794721
189 (Figure 4B). 91% of individuals that were positive for Rh c and e alleles and had no Rh D, C or E
190 alleles, were homozygotes (dosage value > 1.5) for rs55794721. rs55794721 is in LD[19] (R^2 = 0.39) with
191 variant rs586178 tagging certain RhCE blood group alleles[20]. Lead variant in chromosome 7,
192 rs8176058, a known tag SNP for Kell blood group antigen[20] was positively associated with K antigen
193 (Figure 4C). Lead variant in chromosome 9, rs687621[19], is in strong LD, R^2 = 1 with blood group O
194 tagging SNP rs687289[21]. We could also see a strong positive association of rs687621 with blood
195 group antigen O, a positive association with blood group antigen B and a negative association with
196 blood group antigen AB (Figure 4D).



Figure 4 Association of blood group antigens with blood donorship, rs55794721, rs8176058 and rs687621. Blood group antigens K, Dob, D and AB were negatively, and blood group antigen O positively associated to blood donorship. Blood group antigens c and e, belonging to the most common Rh-negative haplotype Rh dce, were positively associated to rs55794721, whereas blood group antigens D, C and E were negatively associated with rs55794721. Blood group antigens Cw and Cx were negatively associated with rs55794721. Blood group antigen K was positively associated with rs8176058. Blood group antigens O and B were positively associated and blood group antigen AB negatively associated with rs687621 in ABO gene.

209 Hemoglobin related associations

210 As hemoglobin value within a specified interval is a required for blood donation eligibility, we
211 investigated whether some of the genome-wide significant variants were associated with
212 hemoglobin. Hemoglobin-related associations were seen in chromosomes 6, 9, 11 and 17 in variants
213 rs9968910, rs3130906, rs687621, rs1135071 and rs199598395, respectively (Supplementary Figure
214 2). We observed a negative association between rs199598395 in RNF43 gene in chromosome 17 and
215 blood donorship. rs199598395 has been previously shown to be Finnish enriched and associated
216 with iron deficiency anemia[22] and to have an effect on blood donation eligibility[23]. Negative
217 association in blood donorship was also seen with rs1135071 in chromosome 11, in a known Finnish
218 enriched Hb variant, Hb Tacoma[24], in HBB gene. Linear regression analysis of blood service
219 operational finger-prick Hb measurements showed a decreasing effect of rs199598395, rs1135071
220 and rs3130906 to hemoglobin level -2.99 g/L ($p = 6.43 \times 10^{-30}$, 95% CI [-3.49, -2.5]), -6.46 g/L ($p = 6.66$
221 $\times 10^{-28}$, 95% CI [-7.57, -5.35]) and -0.22 g/L ($p = 0.002$, 95% CI [-0.32, -0.11]) respectively, and
222 moderate increasing effect of rs9968910 and rs687621, 0.52 g/L ($p = 4.03 \times 10^{-22}$, 95% CI [0.42-0.62])
223 and to 0.25 g/L ($p = 1.72 \times 10^{-05}$, 95% CI [0.15-0.35]), respectively (Supplementary file 2). In summary,
224 all the alleles of these five variants that had an increasing effect on hemoglobin, were more frequent
225 in blood donors (Table 2).

226 We detected a higher allele frequency, 0.69, of rs9968910, previously shown to be associated with
227 diseases of iron metabolism[18], among patients with clinical hereditary hemochromatosis (ICD10 code
228 E83.1) in FinnGen (N=477) compared to population level frequency in Finland, 0.33[25]. rs9968910 is in
229 weak LD with known HFE mutations causing hemochromatosis: rs1799945 (H63D, $R^2 = 0.18$) and
230 rs1800562 (C282Y, $R^2 = 0.1$)[19].

231

232 Association of the *HLA* alleles

233 Because of the known strong role of the HLA region in immunology and the predisposing risk of
234 certain HLA alleles in autoimmunity[5–8,26], we performed an association study with imputed HLA
235 alleles for blood donor endpoint. We could see a strong association ($p = 1.36 \times 10^{-16}$) with rs9272324
236 in chromosome 6 in *HLA-DQA1* gene in the genome-wide association study of blood donorship
237 (Figure 1B). However, after adjusting with T1D (ICD10 E10 and ICD9 250), no significant association
238 in *HLA-DQA1* gene was seen (Figure 1C). *HLA* association analysis for the blood donor phenotype
239 (Figure 5, upper panel) revealed negative association with *HLA*-alleles in linkage with the well-known
240 T1D risk genotype *HLA-DQ2/DQ8*. *HLA* haplotypes *DRB1*03:01-DRB3*01:01-DQA1*05:01-*
241 *HLADQB1*02:01* and *DRB1*04:01- DRB4*01:03- DQA1*03:01- DQB1*03:02* are known to occur with
242 HLA-DQ2 and HLA-DQ8, respectively. The *HLA* alleles in linkage with *HLA-DQ8* were negatively
243 associated with blood donorship: *DRB1*04:01* (beta = -0.12, FDR = 2.2×10^{-11}), *DRB4*01:03* (beta = -
244 0.06, FDR = 2.75×10^{-8}), *DQA1*03:01* (beta = - 0.09, FDR = 1.16×10^{-8}) and *DQB1*03:02* (beta = -0.09,
245 FDR = 9.99×10^{-9}). HLA-alleles previously shown to be associated with *HFE C282Y* allele in Finland[17]
246 or class II alleles with known protection from T1D[27], *B*07:02* (beta = 0.07, FDR = 5.45e-10^{5}),
247 *DRB1*15:01* (beta = 0.06, FDR = 5.45×10^{-5}), *DQA1*01:02* (beta = 0.05, FDR = 5.45 x -10^{-5}) and
248 *DQB1*06:02* (beta = 0.06, FDR = 9.24 x -10^{-5}) were positively associated with blood donorship. *HLA-*
249 *DRB5*01:01* (beta = 0.06, FDR = 5.45×10^{-5}) and *HLA-DPB1*05:01* (beta = 0.1, FDR = 0.04) were
250 positively associated with blood donorship. These two alleles are known to TÄHÄN FREK 0.000111
251 Furthermore, *HLA-B*27:05* (beta = -0.07, FDR = 1.96×10^{-3}), a well-known ankylosing spondylitis risk
252 allele[26], was negatively associated with blood donorship. Adjustment with chr6 lead variant,
253 rs9272324 (Figure 5, middle panel), decreased the effect sizes and increased p-values of the above-
254 mentioned *HLA* alleles in linkage with *HLA-DQ8* and *HLA-B*27:05* and increased the p-values of the
255 above mentioned HFE C282Y related *HLA*-alleles above the significance level (Supplementary file 2).
256 Furthermore, when adjusted with the lead *HLA*-allele, *DRB1*04:01* (Figure 5, lower panel), *HLA-*
257 *B*27:05* (beta = -0.08, FDR = 2.84×10^{-04}) and *HLA-C*02:02* (beta = -0.06, FDR = 2.95×10^{-02}) in LD (r^2
258 = 0.3) with *HLA-B*27:05*, HLA-alleles in linkage with the T1D risk genotype *HLA-DQ2*; *DRB1*03:01*

(beta = -0.05, FDR = 4.31 x 10^{-03}), *DQA1*05:01* (beta = -0.06, FDR = 2.45 x 10^{-03}), *DQB1*02:01* (beta = -0.06, FDR = 4.31 x 10^{-03}) and *HLA-B*08:01* (beta = -0.05, FDR = 4.2 x 10^{-02}), a known *HLA-B* allele in in linkage with *HLA-DQ2* in Finland, were negatively associated with blood donorship (Figure 4, lower panel). In *HLA-DRB1*04:01* adjusted analysis, HFE C282Y related *HLA* alleles *B*07:02*, *DRB1*15:01*, *DQA1*01:02* and *DQB1*06:02* were positively associated with blood donorship, but with lower p-values than in *HLA*-association analysis without any adjustment (Supplementary file 2).



Figure 5. Conditional *HLA* association analysis. Upper panel: *HLA* association analysis for blood donorship. Middle panel: *HLA* association analysis for blood donorship adjusted with rs9272324. Lower panel: *HLA* association analysis for blood donorship adjusted with *HLA-DRB1**04:01. Covariates used in all the analysis: age, sex, BMI, PC1-10, birth region and FinnGen genotyping array version. Dotted horizontal line corresponds to the highest p-value that still fits the FDR limit of 0.05.

273 Variants altering protein expression levels

274 To investigate the function of the lead GWAS variants more closely, we employed protein
275 quantitative trait loci (pQTL) and functional enrichment analyses. Of the 41 fine-mapped and five
276 MHC region variants, 14 were found to be significantly associated (FDR <0.05) with 81 unique plasma
277 protein expression levels (Table 2). Most of the associations, comprising 63 unique proteins, were
278 found with rs687621 located in the *ABO* gene. These included genes that encode for proteins
279 fundamental to the histo-blood group ABO formation, such as *ABO* antigens and *FUT1*. The latter is
280 needed in the fucosylation of the precursor *H* antigen in the ABO biosynthesis[28]. Decreasing effects
281 on expression were seen for e.g. *FUT1*, *VWF*, *F8* and *CLEC4M*, and increasing effects for *ALPI* and
282 *SELE*. Importantly, rs55794721 exerted a decreasing effect on *ICAM4*, a gene encoding for LW
283 glycoprotein present in the RhD protein complex (Figure 6). In addition, two variants were
284 associated with protein expression levels of genes putatively associated with carcinogenesis (Figure
285 6). rs12539059 regulates protein levels of *KLK11*, a kallikrein suspected to play a role in
286 carcinogenesis in human tissues[29]. Another putatively cancer-related[28] protein association was seen
287 for rs60678519 and *GPNMB*. Overexpression of GPNMB has been shown to lead into
288 immunosuppression within tumor immune microenvironment and further into poorer prognosis in
289 variety of cancers[30].

290 The STRING[31] functional enrichment analysis tool identified several functional processes (PPI
291 enrichment p-value < 1×10^{-16}) among the 81 proteins. Gene Ontology (GO) revealed the enrichment
292 of cell adhesion molecules in biological processes and molecular functions. These molecules were
293 further refined to ICAM, C-type lectin and immunoglobulins in protein domains. Other functional
294 categories were blood groups, hemoglobin and iron metabolism, immunology, and cell-cell adhesion
295 (Supplementary file 3).

296 We detected three associations with protein expression level alteration that weren't involved with
297 any of the enriched biological or cellular processes (Supplementary file 3). rs113236240 showed an

298 increasing effect (beta = 0.36) on *PPCDC*, encoding for a protein needed in coentzyme A

299 biosynthesis[28]. rs687621 showed a decreasing effect (beta = -0.4) on *GOLM2*, a proto-oncogene

300 whose overexpression associates with proto-oncogene *HER2/neu*, found in human breast and

301 ovarian cancers[28]. rs1135071 showed a strong increasing effect (beta 2.57) on *AHSP* (Figure 6), which

302 encodes for chaperone protein binding free alpha-globin and therefore having a stabilizing effect in

303 hemoglobin assembly[28].



304

305 Figure 6 Association of the variants to protein expression level alteration. Six variants with
306 association to protein level alteration in pQTL analysis are shown in the figure. The lead variant in
307 ABO gene rs687621, was found to be associated to 63 unique protein level alterations. Lead variant
308 in MHC region in unadjusted GWAS, rs9272324, showed association mainly to immunity related
309 protein level alteration. Variants with decreasing effect on hemoglobin level (Supplementary file 2)
310 rs199598395 and rs1135071 showed association to iron metabolism genes and hemoglobin related
311 gene, respectively. rs6067859 and rs12539059 showed increasing effect on expression of putative
312 cancer-related genes. Variants are annotated if they were significantly (FDR<0.05) associated with
313 protein level alteration. All the variants effecting on protein levels can be found in Table 2 and in
314 more detail in Supplementary file 3.
315

316 Putative bias caused by red cell antigen enrichment in research setting

317 Protective association of red cell antigen O to venous thromboembolism (VTE) has been shown
318 previously by multiple studies[14–16]. To investigate the putative bias an ABO enrichment could cause
319 to VTE association study, we conducted an association analysis with VTE as an endpoint in
320 chromosome 9 (Supplementary Figure 3A) by adjusting for imputed ABO antigens (Supplementary
321 Figure 3). Our results showed that after the adjustment, the p-value of the lead variant failed to
322 reach the genome-wide significance level 5×10^{-8} (rs582118 unadjusted $p = 3.28 \times 10^{-115}$, ABO
323 adjusted $p = 1.16 \times 10^{-6}$) but the signal was not completely removed as some genome-wide
324 significant variants still remained (Supplementary Figure 3A-B). The adjustment not only removed
325 associations of some SNPs but also made visible other variants not detected in the basic analysis
326 (Supplementary Figure 3C).

327

328

329

330

331

332

333

334

335

336

337

338

339 Discussion

340 In the present study we conducted a genome-wide comparison between blood donor biobank
341 donors with relatively long and active blood donation history[17] and FinnGen. The FinnGen control
342 population included individuals from hospital biobanks, population cohorts, and patients at
343 occupational health clinics. As the latter two cohorts comprise largely healthy individuals, and the
344 disease-specific legacy cohorts were excluded from the analysis, the study controls are likely
345 representative of the general Finnish population.

346 The observed protection of blood donors from certain diseases can be directly attributed to donor
347 eligibility criteria that select healthy individuals. However, some of the observed protective genetic
348 factors maybe secondary. For instance, strong negative correlation with anaemia in blood donors
349 could be due to the absence of certain autoimmune diseases, such as Crohn's disease, which can
350 cause anaemia through secondary blood loss. Surprisingly, our results reveal that blood donors not
351 only exhibit a protective genetic profile against diseases explicitly targeted by donor eligibility
352 criteria, but also show a broader negative genetic correlation with conditions beyond these criteria,
353 including various mental illnesses, infectious diseases and Alzheimer's disease. While pleiotropic
354 effects may explain this phenomenon, our analyses indicate that the genetic correlation with the
355 phenotypes targeted by the eligibility criteria is not consistently strong. Further detailed
356 investigations are required to fully understand pleiotropy in blood donor selection and to explore
357 the potential benefits of an active blood donor population for genetic and biomedical research.

358 Expectedly, genetic variants in the MHC region played strong role in several genetic associations as
359 well as in genetic correlation. HLA alleles with known autoimmune associations occurred with lower
360 frequency in the blood donor population than in the control population, whereas hemochromatosis
361 related HLA alleles[17] and HLA alleles with known protective role in autoimmunity, were more
362 frequent among the blood donors.

363 In addition to tagging certain autoimmune-related HLA-alleles or -haplotypes (e.g T1D and
364 ankylosing spondylitis), rs9272324 was shown to enhance the protein levels of *HLA-DRA*, which
365 encodes the nonpolymorphic *DR* alpha-chain[32] essential for the stable expression of DR molecules on
366 the cell surface. Considering this, the known associations of *HLA-DRB1*15:01* in multiple
367 sclerosis[6,33]and the lower frequency of the rs9272324 in blood donors, further investigation of the
368 role of rs9272324 in multiple sclerosis and in autoimmunity in general would be of interest.
369 Furthermore, the significantly higher frequency of rs9968910 and rs9272324 among individuals with
370 clinical hemochromatosis could shed light on the long-discussed low penetrance of the well-
371 described *HFE* variants *C282Y* and *H63D* in clinical hemochromatosis[34].

372 In biomedical research, active blood donors present valuable opportunities due to their positive
373 attitude toward research, availability for longitudinal sampling, and unique genetic makeup.
374 However, when using blood donors exclusively as a control group, it is essential to critically evaluate
375 and interpret the results. The strong immunogenicity of certain blood group antigens,[10–13] as well as
376 the constant need for emergency blood (O RhD neg), leads to the enrichment of these red cell
377 antigens in the blood donor population, as demonstrated in this study.

378 Multiple studies have shown a relationship between the ABO blood group and cardiovascular
379 conditions, specifically noting the decreased risk of thromboembolic events in individuals with blood
380 group O[15,35]. In research settings where blood donors are used as a healthy control population,
381 confounding factors, such as the enrichment of blood group O, should be taken into consideration,
382 as demonstrated by our VTE association analysis.

383 Furthermore, blood group antigen related variants rs55794721 and rs687621 were found to
384 decrease the expression level of genes involved in the function or structure of the cognate blood
385 group molecules. These include the RhD accessory protein ICAM4, the Landsteiner-Wiener
386 glycoprotein[11], and FUT1, a fucosyltransferase necessary in the conversion of the *H* antigen in ABO
387 biosynthesis[16,28,36,37]. The variant rs687621 alone altered expression levels of 63 genes, whose

388 products are involved in various biological pathways. Due to the enrichment of blood group O in the
389 blood donor pool, there was a decreasing effect on proteins involved in hemostasis and thrombosis,
390 such as VWF and F8.

391 Conversely, an increase in protein levels associated with rs687621 was observed for ALPI and SELE.
392 ALPI plays a role in the defense system of the gut mucosal and is thought to prevent bacterial
393 translocation, while SELE is speculated to have role in atherosclerosis. Both of these immunity and
394 cardiovascular related functions are well-known roles of ABO blood group
395 antigens[14,15,36,38].Additionally, another significant finding was the variant rs55794721, which was
396 shown to tag the most frequent RhD negative haplotype in individuals of European ancestry, Rh dce.

397 In addition to hemochromatosis, the results of the present study highlight genetic factors that may
398 affect recipient matching or donation activity. We show a lower expression level of AHSP protein in
399 blood donors due to the lower frequency of rs1135071, which was also shown to decrease the
400 hemoglobin level in this study. Consequently, blood donors exhibited higher hemoglobin levels.
401 AHSP plays a crucial role in hemoglobin assembly by stabilizing the αHb subunits and preventing the
402 self-aggregation of excess αHb subunits prior the formation of HbA1 subunit[39]. To our knowledge, no
403 earlier studies have indicated an increasing effect of *Hb Tacoma* variant rs1135071 on AHSP levels.
404 Given the speculated role of AHSP as a genetic modifier in β-thalassemia[39,40] and the described
405 normal clinical phenotype of *Hb Tacoma* heterozygotes[41], rs1135071 could be of further interest in
406 β-thalassemia research.

407 Furthermore, regarding donor health, it may be useful to analyze whether blood donation is
408 harmless for *Hb Tacoma* heterozygotes or whether the blood products are suitable for recipients
409 with conditions such as sickle cell disease[42]. The known association of rs199598395 with iron
410 deficiency[18], its effect on blood donation eligibility,[23] and the decreasing effect on hemoglobin levels
411 demonstrated in this study support the need for further evaluation of its role in blood donation
412 eligibility or interval.

In this study we present, to our knowledge for the first time, the genetic underpinnings of HDE and blood group-based selection in active blood donors. Our findings highlight the unique genetic makeup of this donor population and its impact on health and blood donation suitability. The results demonstrate the role of genetics in maintaining good health status and active blood donation career that is also connected to a better mental health at the genetic level. Furthermore, research using blood donors as a control group should account for this distinct genetic structure, even after donation ceases. Additionally, the enrichment of specific blood group antigens among blood donors warrants consideration in research as these antigens carry several known disease associations. Further investigations are necessary to fully elucidate the implications of these discoveries, but they underscore the genetic structure behind HDE and the potential of active blood donor cohorts for advancing biomedical genetic research.

Material and Methods

Ethics statement

Study subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr HUS/990/2017. Full list of permits numbers are listed in Supplementary information.

All the sample donors had given a written biobank consent. The use of the data in the present study is in accordance with the biobank consent and meets the requirements of the Finnish Biobank Act

437 688/2012. A formal biobank decision 004-2022 for the research project has been granted by the
438 Finnish Red Cross Blood Service Biobank. The use of the FinnGen data has been accepted with
439 FinnGen proposal F_2022_086.

440

441 Data acquisition

442 Genome data used in the present study originated from samples that were genotyped in the
443 FinnGen project with the FinnGen ThermoFisher Axiom custom array v1 or v2 and genome
444 imputation version R12. Genotyping, quality control, and genome imputation protocols are
445 described in detail in FinnGen Gitbook[43]. In short, genotype calling was performed with GenCall or
446 zCall algorithm for Illumina and AxiomGT1 algorithm for Affymetrix arrays. Prior the imputation,
447 genotyped samples were pre-phased with Eagle 2.3.5 with the default parameters, except the
448 number of conditioning haplotypes was set to 20,000. Genotype imputation was performed using
449 the population-specific imputation reference panel SISu v4.2 with Beagle 4.1 (version 27Jan18.7e1).

450 In addition to genome data, the following electronic health registry data and supplementing data
451 were utilized: ICD (ICD9 and 10) code for type 1 diabetes, occurrence of venous thromboembolism,
452 age, BMI, sex, region of birth and genetic principal components (PC) 1-10. Blood donation data
453 contained blood donation history and hemoglobin value measured at the point of each blood
454 donation event and was used when applicable. Donors with three or less donation events were
455 filtered from the hemoglobin analyses. Blood donation data was available from 44,675 donors.

456 Due to the known selection of healthy individuals as blood donors, legacy samples[43], highly enriched
457 in certain common diseases, were filtered out from the study cohort to minimize possible bias in
458 downstream analyses. Individuals under 18 years of age were removed as 18 is the age limit of blood
459 donation. In addition, individuals born in regions in Finland that were ceded to Soviet Union were
460 filtered out due to age structure of the region and the maximum blood donation age of 70 years. As

461 BMI might influence donor eligibility, individuals lacking BMI information were filtered out. After
462 filtering, total number of FinnGen genome data used in this study was 53,688 cases (blood donors)
463 and 228,060 controls (other FinnGen participants).

464

465 Methods

466 Statistical analyses

467 If not stated otherwise, all statistical analyses were performed in R[44] version 4.3 or 4.4, with
468 RStudio[45]. The genome-wide significance p-value threshold $p < 5 \times 10^{-8}$ was used in GWAS. In all
469 other analyses p-values were adjusted with the Benjamini–Yekutieli procedure[46], and significance
470 threshold of 0.05 was used. All the phenotypes described here, have been previously studied and
471 described in FinnGen in DF12 dataset. At the present, only DF10 data set is publicly available[18].

472

473 Association analysis and fine-mapping

474 Genome-wide association study, GWAS, with an additive genetic model, was performed in FinnGen
475 pipeline with Regenie[47,48] v2.2.4 with blood donor status as a binary endpoint. Sex, age, BMI, PC1-10,
476 birth region, and FinnGen genotyping array version were used as covariates in the GWAS. To
477 discover associations independent of type 1 diabetes (T1D) in chromosome 6, the FinnGen T1D
478 endpoint [22] was used as an additional covariate in the chromosome 6 association analysis.

479 Fine-mapping for the genome wide significant signals ($p < 5 \times 10^{-8}$) of the association study was
480 performed in FinnGen pipeline[48] with SuSiE[49] excluding MHC region (GRCh38, chr6:25-34 Mb)[22,43].
481 For each fine-mapped locus we accepted the credible set as an independent hit if the strongest
482 primary p-value was $p < 5 \times 10^{-8}$. In case of multiple credible sets within a single locus, to accept the
483 secondary hit, we required genome-wide significance and $\log_{10}$(Bayes factor) > 2. As the MHC region
484 is excluded from the fine-mapping pipeline due to its strong LD, the lead variants from the T1D

485 adjusted association analysis, rs9968910, rs10947114, rs3130906 and rs4713637, were selected for
486 the downstream analysis. Moreover, the lead variant in the MHC region in GWAS, rs9272324, was
487 included in the further analyses due to its strong association in autoimmunity[18] and the
488 hypothesized lower association with autoimmunity among blood donors.

489 Association analysis for all the covariates used in GWAS and the imputed blood groups to the blood
490 donor end point was performed with logistic regression in R. We further analyzed the association of
491 all the covariates used in GWAS and imputed blood group antigens to the lead variants in dosage
492 form in chromosomes 1 (rs55794721), 7 (rs8176058) and 9 (rs687621) by using linear regression.

493 Association testing of each classical *HLA* allele *HLA-A*, *-B*, *-C*, *-DRB1*, *-DQA1*, *-DQB1*, *DPB1* and *HLA-*
494 *DRB3-5* for the blood donor endpoint was performed using Regenie v3.0.1. First, a genotype data set
495 for fitting Regenie null models was formed with Plink2 v2.00a4LM using FinnGen DF12 HapMap3
496 variants as a basis and randomly thinning the variants to 500 000 with further filtering for minor
497 allele frequency at least 0.1, Hardy-Weinberg equilibrium greater than p-value 1e-15 and minimum
498 allele count at least 100. Second, the Regenie null models were fitted on the filtered genotype data
499 and used in the association step to take consanguinity into account. To dissect the HLA signal
500 further, two additional association tests were performed: i) conditioning for GWAS chromosome 6
501 lead variant rs9272324 allele and ii) conditioning for the HLA allele dosage with the strongest
502 association, *HLA-DRB1*04:01*, in the primary HLA association analysis.

503 To understand the putative bias caused by red cell antigen, ABO, enrichment in the blood donor
504 pool, we conducted an association study in chromosome 9 in FinnGen pipeline with Regenie[47,48]
505 v2.2.4 with FinnGen venous thromboembolism[22] as a binary endpoint. Sex, age, PC1-10, FinnGen
506 genotyping array version, and FinnGen batch information were used as covariates. In the primary
507 analysis there were 19,957 cases and 344,672 controls. The primary analysis was conditioned with
508 imputed ABO red cell antigens. After filtering out 20 individuals based on low posterior probability of
509 the imputed ABO antigens, 19,956 cases and 344,653 controls remained in the conditional analysis.

510

511 Genetic correlation

512 All pair-wise genetic correlations between blood donorship, hemoglobin and all the 2470
513 phenotypes previously studied as part of FinnGen study were computed using LD Score Regression
514 v1.0.1 using Finnish LD panel in FinnGen pipeline[48]. The computation was based on the GWAS
515 summary statistics previously obtained using Regenie for each phenotype. We used the Benjamini-
516 Yekutieli method to control FDR of genetic correlation at level 0.05. Genetic correlation between
517 groups of phenotypes was approximated as the average of all the pair-wise genetic correlations
518 between the groups.

519

520 HLA and blood group imputation

521 The alleles of the classical HLA genes, *HLA-A*, *-C*, *-B*, *-DRB1*, *DRB3-5*, *-DQA1*, *-DQB1*, and *-DPB1*, had
522 been previously imputed at four-field resolution (i.e., defining protein sequence variation) in
523 FinnGen using HIBAG[50] algorithm with population-specific refence panel as reported earlier[51]. The
524 dosage value of each HLA-allele was used in downstream analyses. Altogether 37 Red Blood cell,
525 *RBC*, antigens in 14 different blood group systems were imputed using random forest models as
526 described by Hyvärinen et al[52]. After imputation, *P1*, *A1* and *A2* antigens were excluded from
527 downstream analyses due to uncertain frequency at the population level. In addition, blood group
528 antigens *HrS* and *HrB*, occurring mainly in African population, are in high correlation with blood
529 group antigen *e* and have low clinical significance (consultation with expert at Finnish Red Cross
530 Blood Service), hence they were excluded from further analyses. After imputation, the samples were
531 filtered based on the posterior probability, PP, value; samples with PP < 0.5 were considered as
532 antigen negative and samples with PP ≥ 0.5 were considered as antigen positive. Altogether 13

533 individuals were excluded from downstream blood group related analyses due to all PP values in
534 ABO being < 0.5.

535

536 pQTL

537 Protein quantitative trait loci, pQTL, analysis had been previously performed in FinnGen[48,53] with
538 multiplex antibody-based immunoassay and multiplex aptamer-based immunoassay, Olink and
539 SomaScan[54], respectively, to detect associations between genetic variants and measured protein
540 levels. We extracted the proteomics summary statistics data for the 41 fine-mapped and the five
541 MHC lead variants in the present study from both datasets, Olink and SomaScan, and filtered the
542 results for statistical significance at FDR < 0.05 level.

543 To evaluate the enrichment of the associated proteins in functional processes, we used STRING
544 interaction network and functional enrichment analysis tool[31].

545

546

547 Data Availability

548 FinnGen summary statistics are available at www.finngen.fi. Data supporting the current study are
549 available from the authors upon reasonable request and with permission of FinnGen.

550 The GWAS results for the blood donor phenotype are available at GWAS catalogue under accession
551 number XXXXX.

552

553 **Code Availability**

554 Code is available in GitHub XXXXXX

555

556

557

558

559

560

561

562 References

563 1. Mitchell, R. Blood banks, biobanks, and the ethics of donation. *Transfusion* **50**, 1866–1869
564 (2010).

565 2. Raivola, V., Snell, K., Helén, I. & Partanen, J. Attitudes of blood donors to their sample and
566 data donation for biobanking. *Eur. J. Hum. Genet.* **27**, 1659–1667 (2019).

567 3. Raivola, V., Snell, K., Helen, I. & Partanen, J. Attitudes of blood donors to their sample and
568 data donation for biobanking. *Eur. J. Hum. Genet.* **27**, 1659–1667 (2019).

569 4. Finnish Red Cross Blood Service - donation eligibility.
570 https://www.veripalvelu.fi/en/faq/?search=&category=eligibility.

571 5. Hu, X. *et al.* Additive and interaction effects at three amino acid positions in HLA-DQ and
572 HLA-DR molecules drive type 1 diabetes risk. *Nat. Genet.* **47**, 898–905 (2015).

573 6. De Silvestri, A. *et al.* The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic
574 Review with Meta-analysis. *Dis. Markers* **2019**, 1409069 (2019).

575 7. Dendrou, C. A., Petersen, J., Rossjohn, J. & Fugger, L. HLA variation and disease. *Nat. Rev.*
576 *Immunol.* **18**, 325–339 (2018).

577 8. Ritari, J., Koskela, S., Hyvärinen, K., FinnGen & Partanen, J. HLA-disease association and
578 pleiotropy landscape in over 235,000 Finns. *Hum. Immunol.* **83**, 391–398 (2022).

579 9. Atsma, F., Veldhuizen, I., Kort, W. De & Vegt, F. De. Healthy donor effect: its magnitude in
580 health research among blood donors. *Transfusion* **51**, 1820–1828 (2011).

581 10. Marsh, W. L. & Redman, C. M. The Kell blood group system: a review. *Transfusion* **30**, 158–
582 167 (1990).

583 11. Avent, N. D. & Reid, M. E. The Rh blood group system: a review. *Blood* **95**, 375–387 (2000).

584 12. Levine, P. & Stetson, R. E. Landmark article July 8, 1939. An unusual case of intra-group
585 agglutination. By Philip Levine and Rufus E Stetson. *JAMA* **251**, 1316–1317 (1984).

586 13. GIBLETT, E. R. A critique of the theoretical hazard of inter vs. intra-racial transfusion.
587 *Transfusion* **1**, 233–238 (1961).

588 14. Stowell, S. R. & Stowell, C. P. Biologic roles of the ABH and Lewis histo-blood group antigens
589 part II: thrombosis, cardiovascular disease and metabolism. *Vox Sang.* **114**, 535–552 (2019).

590 15. Dahlén, T., Clements, M., Zhao, J., Olsson, M. L. & Edgren, G. An agnostic study of associations
591 between ABO and RhD blood group and phenome-wide disease risk. *Elife* **10**, (2021).

592 16. Ward, S. E., O'Sullivan, J. M. & O'Donnell, J. S. The relationship between ABO blood group,
593 von Willebrand factor, and primary hemostasis. *Blood* **136**, 2864–2874 (2020).

594 17. Clancy, J. *et al.* Blood donor biobank as a resource in personalised biomedical genetic
595 research. *Eur. J. Hum. Genet.* (2024) doi:10.1038/s41431-023-01528-0.

596 18. FinnGen. FinnGen Result Browser. https://r10.finngen.fi/ (2024).

597 19. National Institutes of Health LDlink. https://ldlink.nih.gov/?tab=home.

598 20. ISBT Blood Group Allele Tables. https://www.isbtweb.org/isbt-working-parties/rcibgt/blood-
599 group-allele-tables.html.

600 21. Li, S. & Schooling, C. M. A phenome-wide association study of ABO blood groups. *BMC Med.*
601 **18**, 334 (2020).

602 22. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
603 population. *Nature* **613**, 508–518 (2023).

604 23. Toivonen, J., Allara, E., Castrén, J., di Angelantonio, E. & Arvas, M. The value of genetic data
605 from 665,460 individuals in managing iron deficiency anaemia and suitability to donate
606 blood. *Vox Sang.* **119**, 34–42 (2024).

607 24. Kangastupa, P. *et al.* The prevalence of hemoglobin Tacoma in Finland detected by HbA1c
608 capillary electrophoresis. *Scand. J. Clin. Lab. Invest.* **83**, 51–57 (2023).

609 25. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in
610 141,456 humans. *Nature* **581**, 434–443 (2020).

611 26. Bowness, P. HLA-B27. *Annu. Rev. Immunol.* **33**, 29–48 (2015).

612 27. Simmons, K. M. *et al.* Failed Genetic Protection: Type 1 Diabetes in the Presence of HLA-
613 DQB1*06:02. *Diabetes* **69**, 1763–1769 (2020).

614 28. Sayers, E. W. *et al.* Database resources of the national center for biotechnology information.
615 *Nucleic Acids Res.* **50**, D20–D26 (2022).

616 29. Borgoño, C. A., Michael, I. P. & Diamandis, E. P. Human tissue kallikreins: physiologic roles
617 and applications in cancer. *Mol. Cancer Res.* **2**, 257–280 (2004).

618 30. Lazaratos, A.-M., Annis, M. G. & Siegel, P. M. GPNMB: a potent inducer of
619 immunosuppression in cancer. *Oncogene* **41**, 4573–4590 (2022).

620 31. Szklarczyk, D. *et al.* The STRING database in 2023: protein-protein association networks and
621 functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res.* **51**,
622 D638–D646 (2023).

623 32. Brown, J. H. *et al.* Three-dimensional structure of the human class II histocompatibility
624 antigen HLA-DR1. *Nature* **364**, 33–39 (1993).

625 33. Goodin, D. S., Khankhanian, P., Gourraud, P.-A. & Vince, N. Highly conserved extended
626 haplotypes of the major histocompatibility complex and their relationship to multiple
627 sclerosis susceptibility. *PLoS One* **13**, e0190043 (2018).

628 34. Miller, D. T. *et al.* ACMG SF v3.0 list for reporting of secondary findings in clinical exome and
629 genome sequencing: a policy statement of the American College of Medical Genetics and
630 Genomics (ACMG). *Genet. Med.* **23**, 1381–1390 (2021).

631 35. Groot, H. E. *et al.* Genetically Determined ABO Blood Group and its Associations With Health
632 and Disease. *Arterioscler. Thromb. Vasc. Biol.* **40**, 830–838 (2020).

633 36. Stowell, C. P. & Stowell, S. R. Biologic roles of the ABH and Lewis histo-blood group antigens
634 Part I: infection and immunity. *Vox Sang.* **114**, 426–442 (2019).

635 37. Daniels, G. The molecular genetics of blood group polymorphism. *Hum. Genet.* **126**, 729–742

(2009).

38. Franchini, M., Favaloro, E. J., Targher, G. & Lippi, G. ABO blood group, hypercoagulability, and cardiovascular and cancer risk. *Crit. Rev. Clin. Lab. Sci.* **49**, 137–149 (2012).

39. Che Yaacob, N. S., Islam, M. A., Alsaleh, H., Ibrahim, I. K. & Hassan, R. Alpha-hemoglobin-stabilizing protein (AHSP): a modulatory factor in β-thalassemia. *Int. J. Hematol.* **111**, 352–359 (2020).

40. dos Santos, C. O. & Costa, F. F. AHSP and beta-thalassemia: a possible genetic modifier. *Hematology* **10**, 157–161 (2005).

41. Giardine, B. *et al.* Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. *Nucleic Acids Res.* **42**, D1063-9 (2014).

42. Rutherford-Parker, N. J., Colby, J. M., Gehrie, E. A. & Booth, G. S. Unrecognized Hemoglobin Variants in the Donor Blood Supply Are Detectable in the Transfused Population. *Am. J. Clin. Pathol.* **154**, 494–498 (2020).

43. FinnGen. FinnGen Documentation of data release. https://finngen.gitbook.io/documentation/ (2024).

44. R Core Team. https://www.r-project.org/.

45. R studio. https://www.rstudio.com/.

46. Benjamini, Y. & Yekutieli, D. The control of the false discovery rate in multiple testing under dependency. *Ann. Stat.* **29**, 1165–1188 (2001).

47. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and binary traits. *Nat. Genet.* **53**, 1097–1103 (2021).

48. FinnGen gitbook. https://github.com/FINNGEN/.

49. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A Simple New Approach to Variable Selection in Regression, with Application to Genetic Fine Mapping. *J. R. Stat. Soc. Ser. B Stat. Methodol.* **82**, 1273–1300 (2020).

50. Zheng, X. *et al.* HIBAG - HLA genotype imputation with attribute bagging. *Pharmacogenomics J.* **14**, 192–200 (2014).

51. Ritari, J. *et al.* Increasing accuracy of HLA imputation by a population-specific reference panel in a FinnGen biobank cohort. *NAR Genomics Bioinforma.* **2**, (2020).

52. Hyvärinen, K. *et al.* A machine-learning method for biobank-scale genetic prediction of blood group antigens. *PLoS Comput. Biol.* **20**, e1011977 (2024).

53. FinnGen. FinnGen Documentation. https://finngen.gitbook.io/finngen-handbook (2024).

54. Suhre, K., McCarthy, M. I. & Schwenk, J. M. Genetics meets proteomics: perspectives for large population-based studies. *Nat. Rev. Genet.* **22**, 19–37 (2021).

Acknowledgements:

674 We want to acknowledge the participants and investigators of FinnGen study. The FinnGen project is
675 funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the
676 following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb
677 (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp & Dohme
678 LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc.,
679 Maze Therapeutics Inc., Janssen Biotech Inc, Novartis Pharma AG, and Boehringer Ingelheim
680 International GmbH. Following biobanks are acknowledged for delivering biobank samples to
681 FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki
682 Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland
683 (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-
684 English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-
685 US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland
686 (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki),
687 Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta),
688 Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and
689 Arctic Biobank (https://www.oulu.fi/en/university/faculties-and-units/faculty-medicine/northern-
690 finland-birth-cohorts-and-arctic-biobank). All Finnish Biobanks are members of BBMRI.fi
691 infrastructure (www.bbmri.fi). Finnish Biobank Cooperative -FINBB (https://finbb.fi/) is the
692 coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed through
693 the Fingenious® services (https://site.fingenious.fi/en/) managed by FINBB.

694 In addition, we want to acknowledge Dr Katri Haimila for her valuable advice with red cell antigen
695 immunogenetics, Dr Kati Hyvärinen for her expertise and kind help with red cell antigen imputation
696 and the personnel of Blood Service Biobank for their kind help and support for the study.

697

698 Author Contributions

699 Original study concept by JC and JR. Genetic and statistical analysis of the study: JC, JT, MA and JR.
700 Visualization: JC, JT and JR. Medical expertise: JL. FinnGen: data curation and resources. Procedures
701 in the Blood Service Biobank: SK. Original manuscript: JC. JC, JT, JL, SK, JP, FinnGen, MA, JR read,
702 commented, and approved the final manuscript.

703 Competing Interests

704 The authors declare no competing interests.